CO6251331A2 - Inhibicion de arni de expresion de alfa-enac - Google Patents

Inhibicion de arni de expresion de alfa-enac

Info

Publication number
CO6251331A2
CO6251331A2 CO09142201A CO09142201A CO6251331A2 CO 6251331 A2 CO6251331 A2 CO 6251331A2 CO 09142201 A CO09142201 A CO 09142201A CO 09142201 A CO09142201 A CO 09142201A CO 6251331 A2 CO6251331 A2 CO 6251331A2
Authority
CO
Colombia
Prior art keywords
sense
chain
nucleotides
percent
agents
Prior art date
Application number
CO09142201A
Other languages
English (en)
Spanish (es)
Inventor
Heeke Gino Van
Emma Hickman
Henry Luke Danahay
Pamela Tan
Anke Geick
Hans Peter Vornlocher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6251331A2 publication Critical patent/CO6251331A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO09142201A 2007-06-15 2009-12-11 Inhibicion de arni de expresion de alfa-enac CO6251331A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07110376 2007-06-15
EP07114265 2007-08-13

Publications (1)

Publication Number Publication Date
CO6251331A2 true CO6251331A2 (es) 2011-02-21

Family

ID=40130244

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09142201A CO6251331A2 (es) 2007-06-15 2009-12-11 Inhibicion de arni de expresion de alfa-enac

Country Status (26)

Country Link
US (12) US7718632B2 (enExample)
EP (7) EP2223693B1 (enExample)
JP (6) JP5485146B2 (enExample)
KR (2) KR101653008B1 (enExample)
CN (1) CN101778941B (enExample)
AR (1) AR066984A1 (enExample)
AU (1) AU2008263876B2 (enExample)
BR (1) BRPI0813680A8 (enExample)
CA (1) CA2690674C (enExample)
CL (1) CL2008001756A1 (enExample)
CO (1) CO6251331A2 (enExample)
CR (1) CR11136A (enExample)
CU (1) CU23774A3 (enExample)
EA (1) EA200901653A1 (enExample)
EC (1) ECSP099794A (enExample)
ES (6) ES2432158T3 (enExample)
GT (1) GT200900315A (enExample)
IL (1) IL202366A0 (enExample)
MA (1) MA31564B1 (enExample)
MX (1) MX2009013609A (enExample)
PE (1) PE20090942A1 (enExample)
SG (3) SG10201404955RA (enExample)
SV (1) SV2009003434A (enExample)
TN (1) TN2009000521A1 (enExample)
TW (3) TWI552753B (enExample)
WO (1) WO2008152131A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2322145T3 (es) 2002-07-26 2009-06-17 Novartis Vaccines And Diagnostics, Inc. Moleculas pequeñas modificadas de adn inerferente y procedimiento de uso.
KR100473148B1 (ko) * 2002-11-27 2005-03-10 (주)텔리언 버스트모드 패킷 전달을 위한 정합장치 및 방법
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
EP1796732B1 (en) * 2004-10-01 2013-10-30 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
CA2744694A1 (en) * 2008-11-26 2010-06-03 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of epithelial sodium channel (enac) gene expression using short interfering nucleic acid (sina)
CN103275978B (zh) * 2009-04-03 2014-10-29 百奥迈科生物技术有限公司 修饰的小干扰核酸及其制备方法
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
US8563710B2 (en) 2009-04-03 2013-10-22 Biomics Biotechnologies Co., Ltd. Modified oligonucleotide and its preparation and application
US20120207818A1 (en) * 2009-07-14 2012-08-16 Shinohara Fumikazu Composition for suppressing expression of target gene
WO2011046983A2 (en) * 2009-10-12 2011-04-21 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
EP3406720A1 (en) 2009-12-18 2018-11-28 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
CA3098080A1 (en) 2010-04-23 2011-10-27 Arrowhead Research Corporation Organic compositions to treat beta-enac-related diseases
WO2012138416A1 (en) 2011-04-08 2012-10-11 Bio-Rad Laboratories, Inc. Pcr reaction mixtures with decreased non-specific activity
CA2871089A1 (en) 2011-04-20 2012-10-26 Smith Holdings, Llc Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity
RU2631805C2 (ru) * 2011-06-21 2017-09-26 Элнилэм Фармасьютикалз, Инк. Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
JP2014525435A (ja) 2011-09-02 2014-09-29 ノバルティス アーゲー Ｈｓｆ１関連疾患を処置するための有機組成物
KR102634762B1 (ko) 2016-11-01 2024-02-06 애로우헤드 파마슈티컬스 인코포레이티드 알파-v 베타-6 인테그린 리간드 및 그의 용도
TN2019000308A1 (en) * 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
PE20200749A1 (es) * 2017-10-31 2020-07-24 Ionis Pharmaceuticals Inc Moduladores de la expresion de enac
BR112020006901A2 (pt) * 2017-11-01 2020-10-13 Arrowhead Pharmaceuticals, Inc. ligantes de integrina e usos dos mesmos
CN109364248B (zh) * 2018-10-16 2021-05-18 哈尔滨医科大学 ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
EP4021413A4 (en) * 2019-08-30 2023-07-05 United States Government as Represented by The Department of Veterans Affairs LIPOSOMAL TROPONOID COMBINATION FORMULATIONS
US12415840B2 (en) 2020-02-21 2025-09-16 Brookhaven Science Associates, Llc Modified form of oleosin that when expressed in plants leads to increased triacylglycerol (oil) accumulation
MX2023011909A (es) 2021-04-08 2023-10-18 Arrowhead Pharmaceuticals Inc Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso.
US11957178B2 (en) 2021-11-15 2024-04-16 Apackaging Group Llc Aerosol actuator

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3604625C2 (de) * 1986-02-14 1994-01-20 Bmw Rolls Royce Gmbh Gasturbine
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5451670A (en) * 1987-12-09 1995-09-19 City Of Hope Restriction fragment length polymorphism test for haplotyping domesticated fowl
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5013566A (en) * 1988-12-19 1991-05-07 Sampson Michael James Process for obtaining improved yields from plants used for hay making by using a coating agent
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
CA2156288C (en) 1993-02-19 2005-10-18 Junichi Yano Glycerol derivative, device and pharmaceutical composition
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
JP3543347B2 (ja) * 1994-01-24 2004-07-14 日本油脂株式会社 点火薬造粒物の製造方法
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
EP0843555B1 (en) 1995-08-01 2003-08-27 Isis Pharmaceuticals, Inc. Liposomal oligonucleotide compositions
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US5865710A (en) * 1996-08-01 1999-02-02 Wilson-Hyde; Cynthia Step aerobic platform
CA2283293A1 (en) * 1997-03-11 1998-09-17 Yale University Method to diagnose and treat pathological conditions resulting from deficient ion transport such as pseudohypoaldosteronism type-1
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US5976849A (en) 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase
AU767195B2 (en) 1999-03-10 2003-11-06 Phogen Limited Delivery of substances to cells
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20030064385A1 (en) 2001-05-16 2003-04-03 Dressman Marlene Michelle Genes expressed in breast cancer as prognostic and therapeutic targets
EP1478655A4 (en) 2001-12-31 2006-05-10 Algos Therapeutics Inc METHODS AND SUBSTANCES FOR ENAC-BETA MODULATION
ES2322145T3 (es) 2002-07-26 2009-06-17 Novartis Vaccines And Diagnostics, Inc. Moleculas pequeñas modificadas de adn inerferente y procedimiento de uso.
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
EP2213738B1 (en) * 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
EP1573045A4 (en) 2002-11-27 2007-02-21 Artesian Therapeutics Inc DETECTION OF GENES RELATED TO HEART FAILURE AND THERAPEUTIC ASSAY
EP1567549A1 (en) 2002-11-29 2005-08-31 Basf Aktiengesellschaft Methods for the production of methionine
DE10305213A1 (de) 2003-02-07 2004-08-26 Florian Prof. Dr.med. Lang Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms
AU2004227358B8 (en) * 2003-03-31 2009-12-10 Targeted Genetics Corporation Compounds and methods to enhance rAAV transduction
US7723509B2 (en) * 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
US20050256071A1 (en) * 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
JP4530335B2 (ja) * 2004-02-03 2010-08-25 独立行政法人科学技術振興機構 膀胱に発現する上皮型ナトリウムチャネルに対する阻害薬
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
SE0402832D0 (sv) * 2004-11-18 2004-11-18 Astrazeneca Ab Methods
US7923206B2 (en) * 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
CA2590768A1 (en) * 2004-12-14 2006-06-22 Alnylam Pharmaceuticals, Inc. Rnai modulation of mll-af4 and uses thereof
US8101741B2 (en) * 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US20070149456A1 (en) * 2005-12-13 2007-06-28 University Of Pittsburgh Epithelial sodium channel inhibiting agents and uses therefor
WO2008022309A2 (en) 2006-08-18 2008-02-21 F. Hoffmann-La Roche Ag Polyconjugates for in vivo delivery of polynucleotides
WO2008043561A2 (en) 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)

Also Published As

Publication number Publication date
US20200157550A1 (en) 2020-05-21
US20100210513A1 (en) 2010-08-19
SG169988A1 (en) 2011-04-29
PE20090942A1 (es) 2009-08-05
TWI552753B (zh) 2016-10-11
EP2224004A1 (en) 2010-09-01
EA200901653A1 (ru) 2010-06-30
CL2008001756A1 (es) 2009-02-20
CN101778941A (zh) 2010-07-14
CN101778941B (zh) 2013-05-22
JP2014129373A (ja) 2014-07-10
US20100210514A1 (en) 2010-08-19
MA31564B1 (fr) 2010-08-02
EP2223693A1 (en) 2010-09-01
ES2432157T3 (es) 2013-12-02
TN2009000521A1 (en) 2011-03-31
US20180148726A1 (en) 2018-05-31
US9914927B2 (en) 2018-03-13
US9476052B2 (en) 2016-10-25
GT200900315A (es) 2011-10-05
JP5485146B2 (ja) 2014-05-07
KR20160105530A (ko) 2016-09-06
JP2017222704A (ja) 2017-12-21
EP2223695B1 (en) 2013-07-24
ES2432644T3 (es) 2013-12-04
EP2223694B1 (en) 2013-07-24
AU2008263876B2 (en) 2012-04-12
ES2439277T3 (es) 2014-01-22
SG10201404955RA (en) 2014-10-30
AU2008263876A1 (en) 2008-12-18
EP2224004B1 (en) 2013-07-24
CA2690674A1 (en) 2008-12-18
EP2223695A1 (en) 2010-09-01
CR11136A (es) 2010-01-20
EP2223693B1 (en) 2013-07-24
US20090156529A1 (en) 2009-06-18
KR101653008B1 (ko) 2016-08-31
KR101821081B1 (ko) 2018-01-23
EP2223692A1 (en) 2010-09-01
US20150284726A1 (en) 2015-10-08
US8119612B2 (en) 2012-02-21
IL202366A0 (en) 2011-08-01
JP6680728B2 (ja) 2020-04-15
EP2171059A2 (en) 2010-04-07
US10544418B2 (en) 2020-01-28
TW200911989A (en) 2009-03-16
CU23774A3 (es) 2012-02-15
US20100216971A1 (en) 2010-08-26
EP2223692B1 (en) 2013-07-24
TWI444474B (zh) 2014-07-11
SV2009003434A (es) 2011-03-23
SG10201601846VA (en) 2016-04-28
US7939508B2 (en) 2011-05-10
BRPI0813680A2 (pt) 2015-01-06
TW201636027A (zh) 2016-10-16
EP2223694A1 (en) 2010-09-01
BRPI0813680B1 (pt) 2018-02-06
JP2020094063A (ja) 2020-06-18
ES2432532T3 (es) 2013-12-04
TWI629063B (zh) 2018-07-11
US11208662B2 (en) 2021-12-28
JP5719047B2 (ja) 2015-05-13
WO2008152131A3 (en) 2009-05-28
TW201524510A (zh) 2015-07-01
CA2690674C (en) 2018-09-11
US20220235361A1 (en) 2022-07-28
AR066984A1 (es) 2009-09-23
JP2010530369A (ja) 2010-09-09
ES2432643T3 (es) 2013-12-04
JP7157775B2 (ja) 2022-10-20
US20160376599A1 (en) 2016-12-29
US7943592B2 (en) 2011-05-17
JP6193906B2 (ja) 2017-09-06
KR20100039335A (ko) 2010-04-15
US20100216972A1 (en) 2010-08-26
WO2008152131A2 (en) 2008-12-18
EP2224005B1 (en) 2013-09-11
US7718632B2 (en) 2010-05-18
ECSP099794A (es) 2010-01-29
US9074212B2 (en) 2015-07-07
MX2009013609A (es) 2010-01-20
BRPI0813680A8 (pt) 2018-08-28
US8168606B2 (en) 2012-05-01
ES2432158T3 (es) 2013-12-02
JP2022188234A (ja) 2022-12-20
EP2224005A1 (en) 2010-09-01
JP2015145393A (ja) 2015-08-13
US20220112505A1 (en) 2022-04-14
US20100190714A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
CO6251331A2 (es) Inhibicion de arni de expresion de alfa-enac
PE20210921A1 (es) Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden
ES2526295T3 (es) Compuestos antisentido
MX2014008773A (es) Composiciones y metodos para el uso de ésteres de forbol.
AR090869A1 (es) COMPOSICIONES DE ARNi DE SERPINC1 Y SUS METODOS DE USO
PE20190354A1 (es) Moduladores del factor del complemento b
CO6341574A2 (es) Composiciones de antagonistas dl pd-1 y metodos de uso
AR081082A1 (es) Composiciones organicas para tratar enfermedades relacionadas con beta-enac
AR093835A1 (es) COMPOSICIONES DE ARNi PARA PCSK9 Y METODOS PARA USARLAS
ES2674129T3 (es) Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
AR106135A1 (es) Moduladores de la expresión del sarcoma de la rata de kirsten (kras)
PE20241132A1 (es) Composiciones de arni y metodos para silenciar el angiotensinogeno (agt)
AR068565A1 (es) Composiciones para el tratamiento del cabello
ES2676895T3 (es) Variantes combinatorias de alfa-amilasa
PE20142362A1 (es) Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
ECSP11011310A (es) Análogos carba - nucleósido para tratamiento antiviral
MX2013011721A (es) Metodos para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
PE20211393A1 (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO
AR069168A1 (es) Variantes de alfa -amilasas con propiedades alteradas
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
MX2019005898A (es) Composiciones de arni de serpina 1 y sus métodos de uso.
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
CL2013000407S1 (es) Punta de cuchilla raspadora para transportadora, en forma de prisma triangular sobre cara rectangular, cruzado por agujero; las caras mayores son inclinadas y curvas: la frontal es convexa con tramo inferior concavo y la posterior posee doble tramo concavo, el superior de menor altura; la base tiene surco con cavidad central.
CR20120133A (es) Composiciën de entrega de agente activo atrapado en carbohidrato y articulos que usan el mismo
CR20110011A (es) Sustratos que tienen formulaciones con transferibilidad mejorada.

Legal Events

Date Code Title Description
FC Application refused